Cost-Effectiveness Analysis of Tarlatamab for Small-Cell Lung Cancer in the US and China

A 19.6 KB supplementary document presents a cost-effectiveness analysis comparing tarlatamab versus chemotherapy for small-cell lung cancer after platinum-based therapy. The analysis uses a three-state Markov model with efficacy data from the DeLLphi-304 trial and evaluates outcomes from U.S. and Chinese payer perspectives over a lifetime horizon. The dataset was authored by Xiaoju Liu and published on figshare in April 2026.

Use Cases

• Compare incremental cost-effectiveness ratios (ICERs) based on U.S. and Chinese willingness-to-pay thresholds.
• Analyze the impact of drug price variations on cost-effectiveness using price-simulation analyses.
• Evaluate subgroup cost-effectiveness results that parallel survival benefits.
• Assess the robustness of findings through deterministic and probabilistic sensitivity analyses.

Strengths

• Analysis is based on efficacy inputs reconstructed from the DeLLphi-304 phase III trial.
• Model uses parametric survival extrapolation and Bayesian model averaging over a lifetime horizon.
• Costs are expressed in 2025 U.S. dollars for consistent comparison.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is a 19.6 KB DOCX file, suggesting limited scope and likely summary tables rather than raw model data.

Provenance

Source

figshare

Collection Method

Developed using a three-state Markov model with reconstructed trial data.

Freshness

Last updated 2026-04-24 05:40:05; freshness should be verified.

Geography

United States and China